Codon

AUGUST 26, 2024

Brian Wang (co-founder of the nonprofit Panoplia Laboratories ) outlines his approach to making broad-spectrum antivirals. When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use.

RNA 88

RNA Virus DNA Vaccine 88

Broad Institute

AUGUST 31, 2023

Related News Next generation prime editing systems move closer to possible therapeutic applications New CRISPR genome editing system offers a wide range of versatility in human cells Prime editing technologies allow scientists to precisely edit the genome in a variety of ways and could one day be used to treat genetic diseases.

DNA 145

DNA RNA Engineering Laboratories 145

PerkinElmer

MAY 28, 2020

Time is of the essence when it comes to the development of a vaccine for the novel infectious disease in our current pandemic. Unfortunately, the road towards treatment can be time-consuming, especially when utilizing assays with live virus.

Vaccine 52

Vaccine Disease Virus Small Molecule 52

The Pharma Data

JUNE 26, 2021

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection. However, the discovery does show that the virus can change in unexpected ways and find new ways to cause infection. Now, researchers at Washington University School of Medicine in St. and Hubert C.

Virus 52

Virus Cell Biology Vaccine Research 52

Codon

AUGUST 27, 2024

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.

DNA 86

DNA Laboratories Hospitals Virus 86

Drug Target Review

JANUARY 26, 2024

Researchers from Columbia University and the US Department of Energy (DOE)’s Brookhaven National Laboratory have elucidated a method to produce large quantities of the receptor that the SARS-CoV-2 spike protein uses to bind to the surface of human cells.

Production 114

Production DNA Virus Protein Expression 114

Broad Institute

JANUARY 30, 2024

Bhattacharyya wears many coats today, splitting his time between the Broad and the infectious disease ward at MGH, where a diagnostic method he developed at Broad is now being tested to see if it helps patients quickly receive the best antibiotics for their infections.

Hospitals 137

Hospitals Medical Schools Virus Science 137

Drug Target Review

SEPTEMBER 4, 2023

There have been several studies that have reported the ability of infectious disease agents to be drug resistant. Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. 7,13 The use of Plants extract is important in drug discovery.

Drugs 111

Drugs RNA DNA Disease 111

The Pharma Data

JANUARY 6, 2021

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ sangivamycin) has broad-spectrum antiviral activity in laboratory-based assays against several viruses. ROCHESTER, N.Y. , 7, 2021 /PRNewswire/ — OyaGen, Inc. Bennett et al., About OYA1. OYA1 (a.k.a.

Virus 40

Virus Clinical Trials Government Laboratories 40

SCIENMAG: Medicine & Health

OCTOBER 18, 2023

This study is conducted by the Jiangsu Provincial Center for Disease Control and Prevention, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Vaccines for Infectious Diseases of Xiamen University, China National Institutes for Food and Drug Control, and Xiamen Innovax Biotech Company.

Vaccine 52

Vaccine Laboratories Virus Science 52

Drug Target Review

SEPTEMBER 28, 2023

They needed reference materials for the disease in order to develop and validate diagnostic tests. For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus. These are synthetic, not the live virus, so do not pose a risk of infection.

DNA 116

DNA Organic Chemistry Science Virus 116

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Let’s take a deeper dive into these challenges.

Vaccine 79

Vaccine Immune Response Clinical Trials Disease 79

Drug Target Review

DECEMBER 5, 2024

2 Since then, the FDA has approved four more AAV-based gene therapies—Zolgensma, Hemgenix, Elevidys and Rocktavian—for treating various diseases. 2 Since then, the FDA has approved four more AAV-based gene therapies—Zolgensma, Hemgenix, Elevidys and Rocktavian—for treating various diseases. Signal Transduct Target Ther. 2024;9(1):78.

Therapies 52

Therapies Virus DNA Compliance 52

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. The research team, led by Yan Wu, Capital Medical University, Beijing, first isolated the pair of antibodies in the laboratory, starting with white blood cells from the patient.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

PerkinElmer

JANUARY 25, 2023

Laboratory professionals in all areas of science have experienced significant changes in recent years, and 2022 was no exception. Additionally, chronic disease, cancer and neurodegenerative disorders like Alzheimer’s were top of mind last year for diagnostics and drug R&D teams alike.

Science 52

Science Laboratories Immune Response Disease 52

The Pharma Data

DECEMBER 10, 2020

The FDA said Thursday that it has developed a test for COVID-19 in fecal matter, in an attempt to prevent the disease from being inadvertently transmitted during fecal transplantation. We know now that the viral RNA is found in stool and infectious virus as well. 1, 2019, until effective screening methods are implemented.”.

FDA 52

FDA Laboratories RNA Virus 52

Drug Target Review

JULY 17, 2024

While current polyclonal antibody (pAb) therapies are derived from plasma, GigaGen has developed single-cell discovery and development platforms to produce diverse and potent recombinant pAb therapies that are made in the laboratory. Both recombinant pAbs and plasma-derived antibody therapies can start with donors who are strong responders.

Immune Response 59

Immune Response Therapies Laboratories Vaccine 59

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Virus 40

Virus Trials Clinical Trials Production 40

Codon

FEBRUARY 27, 2024

Patient YY’s neighbors quickly started to become infected, passing on the virus in turn. While the consensus that emerged among experts was that the virus spread primarily via airborne transmission , it also made use of another route: fomite transmission. Puzzled, epidemiologists sought to understand the source of the outbreak.

Virus 68

Virus Hospitals Production Regulations 68

The Pharma Data

MARCH 16, 2021

Pascal Soriot, Chief Executive Officer, said: “The long-acting antibody combination has the potential to offer almost immediate protection to those who are not able to be vaccinated, to both prevent infection or treat the disease in patients already infected with the virus. Financial considerations. Source link:[link].

Treatment 52

Treatment Virus Trials Government 52

The Pharma Data

MARCH 16, 2021

The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission. Among them, mutations E484K, N501Y and del 69-70 are located in the spike protein, the region that enables the virus to attach to and enter the human cell. 1.1.7), South Africa (B.1.351),

Clinical Trials 52

Clinical Trials Laboratories Virus Vaccine 52

Codon

DECEMBER 12, 2024

Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine. In 2001, in an outbreak that had nothing to do with a lab leak, foot-and-mouth disease in the U.K.

DNA 100

DNA RNA Vaccine Virus 100

The Pharma Data

SEPTEMBER 28, 2021

Patients with respiratory infections often have signs and symptoms that are indicative of the disease, but aren’t specific enough to discern the basis explanation for the illness. Addition of those tests will equip health systems to combat new respiratory diseases once they arise.

Marketing 52

Marketing Virus DNA Disease 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. 3 Knowing a given population’s seroprevalence is important in understanding how to contain the spread of the virus, as well as how to safely ease lockdown restrictions.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

SEPTEMBER 14, 2020

Monoclonal antibodies, which are potent, laboratory-made antibodies, will be given to about 2,000 people to see if they are effective against coronavirus. Prof Martin Landray from the University of Oxford, who is co-leading the Recovery Trial, said: “This is the first type of treatment that’s targeted for this specific virus.

Trials 52

Trials Immune Response Virus Vaccine 52

Creative Biolabs

JULY 12, 2020

They reconstructed 255 antibodies in the laboratory and tested their ability to neutralize novel coronavirus SARS-CoV-2 by the Stephan Becker laboratory at University of Marburg. This means that only minor changes are needed to effectively identify and neutralize the virus. They found a total of 28 neutralizing antibodies.

Immune Response 52

Immune Response Laboratories Clinical Trials Clinical Development 52

The Pharma Data

NOVEMBER 26, 2020

Researchers at Heidelberg University in Germany performed detailed imaging analysis to determine how SARS-CoV-2, the virus that causes COVID-19, reprograms infected cells. The virus causes changes in the membrane so it can produce its own replication organelles, amplifying the viral genome. It only takes 24 to 48 hours.

Research 52

Research Virus Vaccine DNA 52

The Pharma Data

NOVEMBER 29, 2021

1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). Severity of disease : It is not yet clear whether infection with Omicron causes more severe disease compared to infections with other variants, including Delta. Studies underway.

Vaccine 52

Vaccine Virus Disease Hospitals 52

The Pharma Data

NOVEMBER 18, 2020

Antimicrobial resistance occurs when microorganisms resist the effects of medications, making infections harder to treat and increasing the risk of disease spread, severe illness and death. HIV drug resistance is caused by changes in the genetic structure of HIV that affects the ability of drugs to block the replication of the virus.

Laboratories 52

Laboratories Therapies Virus Government 52

The Pharma Data

NOVEMBER 9, 2021

Among the populations most significantly affected by COVID-19 are the elderly and patients with preexisting medical conditions including diabetes, hypertension, obesity, metabolic syndrome, cardiovascular disease and chronic lung diseases like COPD and asthma. What’s more, chitinase 3-like-1 augments SARS CoV-2 infection.”

Small Molecule 52

Small Molecule Virus Molecular Biology Disease 52

Drug Target Review

SEPTEMBER 8, 2023

Remarkably, these findings propose that the presence of a cytoplasmic version of RARα is indispensable for T cells to initiate their defence against diseases. The researchers speculate that this mechanism could serve as a valuable target for combating autoimmune diseases and other inflammatory conditions.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

MARCH 25, 2021

TAK-003 is Being Studied for the Prevention of Dengue Due to any Dengue Virus Serotype in Individuals Ages Four to 60. With limited options to prevent the disease, there is a pressing need for widely available dengue vaccines. About TAK-003. 4,5 Efficacy varied by serotype.

Vaccine 52

Vaccine Virus Trials Hospitals 52

PPD

OCTOBER 24, 2024

Hepatitis B virus (HBV) infection remains a significant public health challenge, particularly in low- and middle-income countries (LMIC) and in the Asia-Pacific region. Coordinated efforts are needed to combat this disease and improve the clinical status of persons with HBV infection.

Vaccine 52

Vaccine Virus Treatment Disease 52

Codon

JULY 21, 2024

Of course, AA and P-line rats are not the only research animals bred for the study of disease. By doing so, researchers study pain, genetic disorders, the effect of drugs, and disease pathways in mammals that, while genetically similar to us, are not human beings. They are bred, incised, injected, and deprived.

Research 113

Research Engineering Disease Science 113

The Pharma Data

SEPTEMBER 1, 2020

Point of care testing increases access to high quality diagnostics solutions for the detection of a current SARS-CoV-2 infection, regardless of laboratory testing infrastructure or patient mobility. This is highly beneficial where timely decisions are needed or laboratory testing is inaccessible.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

The Pharma Data

JANUARY 15, 2021

16, 2021 /CNW/ – As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health , laboratory and healthcare capacity. OTTAWA, ON , Jan.

Virus 40

Virus Laboratories Vaccine Hospitals 40

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. AZD7442 was well tolerated in the trial.

Trials 52

Trials Virus Long-Term Care Facilities Government 52